CVE:PAS Pascal Biosciences (PAS) Stock Price, News & Analysis C$0.02 -0.01 (-25.00%) As of 12/5/2022 Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pascal Biosciences Stock (CVE:PAS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Pascal Biosciences alerts:Sign Up Key Stats Today's RangeC$0.02▼C$0.0250-Day RangeC$0.02▼C$0.0252-Week RangeC$0.02▼C$0.10Volume4,000 shsAverage Volume52,289 shsMarket CapitalizationC$983,850.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPascal Biosciences Inc., a biotechnology company, engages in the research and development of products for the treatment of cancer, and for the improvement of the immune system. The company's development portfolio includes PAS-403, a mitosis inhibitor that blocks cell division for the treatment of glioblastoma and brain metastases originating from other cancers; and PAS-393, an immune-stimulatory cannabinoid designed to restore the immunogenicity of tumor cells with checkpoint inhibitor therapy for use in cancer treatment. It is also developing a B-cell targeted antibody for acute lymphoblastic leukemia and B cell lymphomas; and cannabinoid therapeutic products for the treatment of COVID-19. The company has an exclusive license agreement with the University of Washington to develop a cannabinoid-based product for the treatment of glioblastoma multiforme and brain metastases; and a collaborative research agreement with SoRSE Technology Corporation to advance PAS-393 into clinical testing. Pascal Biosciences Inc. was incorporated in 2011 and is headquartered in Seattle, Washington.Read More… Receive PAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pascal Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address PAS Stock News HeadlinesDebating the New Emmy Awards Strategy Adopted by Pedro Pascal for ‘The Last of Us’: Die Early, Submit for LeadMay 29 at 1:23 PM | msn.comDoctor Who legend David Tennant admits to wanting Fantastic Four role before Pedro Pascal got the partMay 26 at 9:39 AM | msn.comOnly a handful of people know the setup that's defied these chaotic markets.Since February, we've hit 28 out of 29 trades – that's a 96% win rate taking simple options setups on one single ticker every day. That's why Jack Carter and I teamed up to reveal The 4PM Payout Plan. Our goal here was to show you how to take these daily setups every morning to collect a 4PM payout. Naturally, no one can guarantee what the market does in the future… But these simple daily options setups have paid out with the market rallying, dropping, or staying flat. And if you want to be one of the few to not just know the ropes behind these daily setups but also deploy them for yourself…May 29, 2025 | WealthPress (Ad)Pedro Pascal says storytelling is a way to fight fear and push backMay 21, 2025 | apnews.comPedro Pascal’s Emotional Final Goodbye From ‘The Last of Us’ Set Left Fans ReelingMay 21, 2025 | msn.comTitan X Pascal SLI at 5K - PCSpecialist Leviathan X reviewMay 21, 2025 | msn.comPedro Pascal's plunging neck shirt look at Cannes leaves fans swooning: ‘Feeling bad for all the other dudes on planet’May 21, 2025 | msn.comLux Pascal Is a Proud Sister: “Pedro’s Taught Me There’s No Reason to Hide Who I Am”April 28, 2025 | msn.comSee More Headlines PAS Stock Analysis - Frequently Asked Questions How have PAS shares performed this year? Pascal Biosciences' stock was trading at C$0.02 on January 1st, 2025. Since then, PAS shares have increased by 0.0% and is now trading at C$0.02. View the best growth stocks for 2025 here. How do I buy shares of Pascal Biosciences? Shares of PAS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers. What other stocks do shareholders of Pascal Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pascal Biosciences investors own include Aurora Cannabis (ACB), Canadian Natural Resources (CNQ), Corus Entertainment (CJR), Auxly Cannabis Group (CBWTF), Grande West Transportation Group (BUS), Bausch Health Companies (BHC) and Abattis Bioceuticals (ATT). Industry, Sector and Symbol Stock ExchangeCVE SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolCVE:PAS CIKN/A Webwww.biommune.net Phone+1-604-6886775FaxN/AEmployees6Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)C($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-340.40% Debt Debt-to-Equity Ratio882.79 Current Ratio0.03 Quick Ratio0.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowC$0.00 per share Price / Cash Flow55.00 Book ValueC($0.02) per share Price / Book-0.75Miscellaneous Outstanding Shares65,590,000Free FloatN/AMarket CapC$983,850.00 OptionableNot Optionable Beta1.51 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (CVE:PAS) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pascal Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pascal Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.